{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicoevkqhnfw4hzulnp2ksqpcb5s5t6gwbruosaaohflk2sadrc6ze",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmelgloojs52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihkpeq7m3zhnwbmuf6tzte2bcpykiksq6zocj6fibq7k5zgz25pou"
    },
    "mimeType": "image/jpeg",
    "size": 520776
  },
  "path": "/news/2026-05-marker-patients-advanced-prostate-cancer.html",
  "publishedAt": "2026-05-21T09:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.",
  "title": "New marker identifies patients with advanced prostate cancer more likely to benefit from combination immunotherapy"
}